Zevra publishes four-year real-world U.S. early access data on MIPLYFFA in Niemann-Pick disease type C

Findings indicated patients’ overall disease status stayed broadly stable over time in routine clinical practice, including in adults.

Safety observations aligned with the therapy’s established profile, supporting continued use alongside miglustat in eligible patients.

The report reinforces the product’s commercial positioning following its U.S. clearance in 2024, with an EU filing under review.

Zevra Therapeutics published four-year real-world data from its U.S. early access program for MIPLYFFA (arimoclomol) in Niemann-Pick disease type C.

Results were presented as a peer-reviewed journal publication, not a future conference readout.